Arbutus Biopharma Co. (NASDAQ:ABUS) Shares Purchased by Deutsche Bank AG

Deutsche Bank AG increased its holdings in shares of Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) by 77.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 171,766 shares of the biopharmaceutical company's stock after acquiring an additional 75,212 shares during the quarter. Deutsche Bank AG owned about 0.09% of Arbutus Biopharma worth $562,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ABUS. Xponance Inc. purchased a new stake in Arbutus Biopharma in the 4th quarter valued at $34,000. E Fund Management Co. Ltd. acquired a new position in shares of Arbutus Biopharma during the 4th quarter valued at about $34,000. Raymond James Financial Inc. acquired a new position in shares of Arbutus Biopharma during the 4th quarter valued at about $34,000. Cibc World Markets Corp purchased a new stake in shares of Arbutus Biopharma in the fourth quarter valued at about $45,000. Finally, Hsbc Holdings PLC purchased a new stake in shares of Arbutus Biopharma in the fourth quarter valued at about $55,000. 43.79% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ABUS has been the topic of a number of analyst reports. Wall Street Zen raised shares of Arbutus Biopharma from a "sell" rating to a "hold" rating in a research note on Saturday, March 29th. Chardan Capital restated a "buy" rating and set a $5.00 price target on shares of Arbutus Biopharma in a report on Friday, March 28th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $5.50.

Arbutus Biopharma Trading Down 2.3%

ABUS traded down $0.08 on Friday, hitting $3.36. The company had a trading volume of 635,966 shares, compared to its average volume of 991,233. The company's fifty day moving average price is $3.27 and its 200 day moving average price is $3.34. Arbutus Biopharma Co. has a 1 year low of $2.71 and a 1 year high of $4.73. The firm has a market cap of $643.53 million, a P/E ratio of -7.81 and a beta of 1.50.

Arbutus Biopharma (NASDAQ:ABUS - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.04). Arbutus Biopharma had a negative net margin of 1,137.65% and a negative return on equity of 68.18%. The company had revenue of $1.76 million during the quarter, compared to analysts' expectations of $2.54 million. On average, analysts predict that Arbutus Biopharma Co. will post -0.39 earnings per share for the current year.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.